Want to see HK:2225 full AI Analyst Report?
Jinhai International Group Holdings Limited (2225) AI Stock Analysis
Top Page
Jinhai International Group Holdings Limited
(HKEX:2225)
The score is primarily weighed down by weak financial performance: sharp margin compression, sustained net losses, and three years of negative operating/free cash flow. Technicals are mixed but lean weak in the near term (below 20/50-day averages with low RSI/Stoch). Valuation is also unattractive/unclear due to a very negative P/E and no provided dividend yield.
Jinhai International Group Holdings Limited (2225) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 19.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 6.64M
- Price to Earnings (P/E)
- -279.2
- Beta (1Y)
- 0.48
- Revenue Growth
- 75.36%
- EPS Growth
- 49.21%
- Country
- Hong Kong
- Employees
- 472
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Staffing & Employment Services
Jinhai International Group Holdings Limited Business Overview & Revenue Model
Company Description
Jinhai Medical Technology Ltd. specializes in offering workforce solutions and a range of complementary support services. Catering primarily to building and construction contractors, their comprehensive service portfolio encompasses dormitory managem...
Jinhai International Group Holdings Limited Financial Statement Overview
Summary
Despite revenue growth in 2025 (+17.5%), profitability has deteriorated sharply with materially lower gross margin and deep operating/net losses (2025 net margin ~-36.9%). Cash flow is also a key risk: operating and free cash flow have been negative for three consecutive years (2023–2025). The balance sheet leverage appears manageable (debt-to-equity <0.5), but consistently negative ROE highlights ongoing value destruction.
Income Statement
24NegativeBalance Sheet
56NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.07M | 46.28M | 50.24M | 45.64M | 22.28M | 21.90M |
| Gross Profit | 11.79M | 7.19M | 11.48M | 12.03M | 10.12M | 7.73M |
| EBITDA | -4.75M | -13.39M | -15.07M | 1.11M | 5.25M | 5.44M |
| Net Income | -11.23M | -17.08M | -17.96M | -3.14M | 468.00K | -246.21K |
Balance Sheet | ||||||
| Total Assets | 100.24M | 88.83M | 58.87M | 62.22M | 40.27M | 33.77M |
| Cash, Cash Equivalents and Short-Term Investments | 29.25M | 36.78M | 14.93M | 26.76M | 23.95M | 25.91M |
| Total Debt | 14.20M | 14.91M | 14.52M | 10.08M | 4.45M | 1.87M |
| Total Liabilities | 44.58M | 36.87M | 26.09M | 24.73M | 15.68M | 9.75M |
| Stockholders Equity | 51.91M | 51.28M | 31.81M | 37.47M | 24.37M | 24.28M |
Cash Flow | ||||||
| Free Cash Flow | -8.57M | -6.18M | -4.26M | -3.15M | 3.06M | 2.73M |
| Operating Cash Flow | -5.62M | -6.08M | -3.25M | -1.91M | 4.24M | 3.34M |
| Investing Cash Flow | -9.56M | 3.47M | -9.22M | -6.51M | -1.15M | -2.64M |
| Financing Cash Flow | 27.17M | 26.68M | 2.93M | 13.62M | -3.72M | -4.81M |
Jinhai International Group Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2225, the sentiment is Negative. The current price of 3.60 is below the 20-day moving average (MA) of 4.13, below the 50-day MA of 4.90, and above the 200-day MA of 3.54, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 34.77 is Neutral, neither overbought nor oversold. The STOCH value of 34.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2225.
Jinhai International Group Holdings Limited Peers Comparison
Overall Rating
HK:218073Outperform
HK:610059Neutral
HK:691957Neutral- HK:222544Neutral
HK:846241Neutral
HK:803137Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2180 | 73Outperform | HKD 876.71M | 4.54 | 15.17% | 41.89% | 6.09% | 21.21% |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| HK:6100 | 59Neutral | HKD 1.12B | 7.75 | 3.86% | 9.05% | ― | ― |
| HK:6919 | 57Neutral | HKD 516.06M | 3.92 | 8.42% | 7.20% | 9.13% | ― |
| HK:2225 | 44Neutral | HKD 19.13B | -279.20 | -21.76% | ― | 75.36% | 49.21% |
| HK:8462 | 41Neutral | HKD 45.00M | -20.37 | -1.42% | ― | -14.98% | -120.83% |
| HK:8031 | 37Underperform | HKD 77.33M | -2.70 | -43.31% | ― | ― | ― |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2225 | Jinhai International Group Holdings Limited | 3.60 | 2.48 | 221.43% | |
| HK:2180 | ManpowerGroup Greater China Limited | 4.22 | -0.78 | -15.63% | |
| HK:6100 | Tongdao Liepin Group | 2.21 | -0.74 | -25.08% | |
| HK:6919 | Renrui Human Resources Technology Holdings Limited | 3.33 | -1.20 | -26.43% | |
| HK:8031 | ETS Group Limited | 0.22 | 0.04 | 21.11% | |
| HK:8462 | Omnibridge Holdings Ltd. | 0.07 | -0.02 | -23.47% |
Jinhai International Group Holdings Limited Corporate Events
Jinhai Medical Revamps Board and Committees with New Independent Director
Jinhai Medical Technology Limited has restructured its board, appointing finance and audit specialist Ms. Liu Jinjing as an independent non-executive director effective 18 September 2026. Her appointment brings over 15 years of professional experienc...
Jinhai Medical Restructures Board and Committees to Bolster Governance
Jinhai Medical Technology Limited has updated the composition of its board of directors effective 18 September 2026, appointing Mr. Chen Guobao as chairman, Mr. Li Bin as co-chairman and Mr. Wang Zhenfei as chief executive officer, alongside non-exec...
Jinhai Medical Clarifies Use of Listing and Placing Proceeds
Jinhai Medical Technology Limited issued a supplemental announcement to clarify how it has used and plans to use net proceeds from its listing and October 2023 placings up to 31 December 2025. The company detailed reallocations among acquiring a fore...
Jinhai Medical Narrows Interim Loss as Revenue More Than Doubles
Jinhai Medical Technology Limited reported a sharp rise in revenue to S$34.0 million for the six months ended 30 June 2026, more than doubling from S$14.5 million a year earlier, driven by improved business performance. Despite higher cost of sales,...
Jinhai Medical Technology Sets Board Meeting to Approve Interim Results and Consider Dividend
Jinhai Medical Technology Limited has scheduled a board meeting for 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend, indicat...
Jinhai Medical Appoints Veteran CMO to Drive Minimally Invasive Growth
Jinhai Medical Technology Limited has appointed industry veteran Ma Chengdong as its chief marketing officer, effective 3 August 2026 for an initial one-year term, tasking him with leading marketing strategy, market access, academic promotion, sales...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026